Hutchison China MediTech Limited Sponsored ADR Stock

$15.90

1.00% today

Nasdaq, Apr 02, 10:00 pm CET

ISIN

US44842L1035

Symbol

HCM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Hutchison China MediTech Limited Sponsored ADR Stock price

$15.90

-2.03 11.32% 5Y

Nasdaq, Closing price Wed, Apr 02 2025

-0.16 1.00%

ISIN

US44842L1035

Symbol

HCM

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$2.80b
Enterprise Value	$2.07b
P/E (TTM) P/E ratio	74.32
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	3.28
P/S ratio (TTM) P/S ratio	4.45
P/B ratio (TTM) P/B ratio	3.68
Revenue growth (TTM) Revenue growth	-25.48%
Revenue (TTM) Revenue	$629.37m
EBIT (operating result TTM) EBIT	$-43.66m
Free Cash Flow (TTM) Free Cash Flow	$-17.39m
EPS (TTM) EPS	$0.22
P/E forward	7.58
P/S forward	4.00
EV/Sales forward	2.95
Short interest	0.35%

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Get Started for Free Today

Hutchison China MediTech Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

??

25 Analysts have issued a Hutchison China MediTech Limited Sponsored ADR forecast:

23x Buy

92%

More details on Analyst Estimates Including Price Targets

25 Analysts have issued a Hutchison China MediTech Limited Sponsored ADR forecast:

Buy

92%

Hold

Analyst Estimates with Stock Price Targets

Financial data from Hutchison China MediTech Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

TTM Annually

Dec '24		+/- %
Revenue	629 629	25% 25% 100%
- Direct Costs	348 348	10% 10% 55%
Gross Profit	281 281	38% 38% 45%
- Selling and Administrative Expenses	100 100	20% 20% 16%
- Research and Development Expense	212 212	31% 31% 34%
EBITDA	-31 -31	227% 227% -5%
- Depreciation and Amortization	12 12	49% 49% 2%
EBIT (Operating Income) EBIT	-44 -44	367% 367% -7%
Net Profit	38 38	62% 62% 6%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Hutchison China MediTech Limited Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

12 days ago

HUTCHMED Announces NMPA Conditional Approval for TAZVERIK® (tazemetostat) for the Treatment of Relapsed or Refractory Follicular Lymphoma

— First and only EZH2 inhibitor approved by the NMPA — — HUTCHMED's fourth product, and its first approval in hematological malignancies — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for TAZVERIK® (tazemetostat) has been granted conditiona...

Neutral

GlobeNewsWire

●

14 days ago

Intended Retirement of Independent Non-executive Directors and changes of composition of board committees

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:HCM, HKEX:13) today announces that Mr Paul Rutherford Carter and Mr Graeme Allan Jack, who have both served as Independent Non-executive Directors of the Company for more than eight years, have informed the Company that they would not seek re-ele...

Neutral

GlobeNewsWire

●

14 days ago

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

— SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO ® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address mechanisms of resistance in the advanced setting —

More Hutchison China MediTech Limited Sponsored ADR News

Company Profile

Hutchison China MediTech Ltd. is a holding company, which engages in the research and development, manufactures, and sells pharmaceuticals and health oriented consumer products. It operates through the Innovation Platform and Commercial Platform segments. The Innovation Platform segment relates to research and development of innovative therapeutics in oncology and autoimmune diseases. The Commercial Platform segment relates to prescription drugs which develops, manufacture, markets, and sale of prescription pharmaceuticals; and consumer health which comprised of development, manufacture, distribution, and marketing of over-the-counter pharmaceuticals, and consumer health products. The company was founded in June 2000 and is headquartered in Hong Kong.

Head office	Cayman Islands
CEO	Wei Su
Employees	1,811
Founded	2000
Website	www.hutch-med.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now